- Home
- JPI vs CERS Comparison
JPI vs CERS Comparison
Compare JPI & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPI
- CERS
- Stock Information
- Founded
- JPI 2012
- CERS 1991
- Country
- JPI United States
- CERS United States
- Employees
- JPI N/A
- CERS N/A
- Industry
- JPI Finance Companies
- CERS EDP Services
- Sector
- JPI Finance
- CERS Technology
- Exchange
- JPI Nasdaq
- CERS Nasdaq
- Market Cap
- JPI 288.1M
- CERS 255.0M
- IPO Year
- JPI N/A
- CERS 1997
- Fundamental
- Price
- JPI $20.70
- CERS $1.23
- Analyst Decision
- JPI
- CERS Strong Buy
- Analyst Count
- JPI 0
- CERS 2
- Target Price
- JPI N/A
- CERS $3.50
- AVG Volume (30 Days)
- JPI 54.7K
- CERS 1.2M
- Earning Date
- JPI 01-01-0001
- CERS 10-29-2025
- Dividend Yield
- JPI 6.15%
- CERS N/A
- EPS Growth
- JPI N/A
- CERS N/A
- EPS
- JPI N/A
- CERS N/A
- Revenue
- JPI N/A
- CERS $192,510,000.00
- Revenue This Year
- JPI N/A
- CERS $30.03
- Revenue Next Year
- JPI N/A
- CERS $9.37
- P/E Ratio
- JPI N/A
- CERS N/A
- Revenue Growth
- JPI N/A
- CERS 13.25
- 52 Week Low
- JPI $16.02
- CERS $1.12
- 52 Week High
- JPI $19.12
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- JPI 66.91
- CERS 44.31
- Support Level
- JPI $20.15
- CERS $1.17
- Resistance Level
- JPI $20.70
- CERS $1.35
- Average True Range (ATR)
- JPI 0.15
- CERS 0.07
- MACD
- JPI 0.05
- CERS -0.00
- Stochastic Oscillator
- JPI 93.22
- CERS 22.22
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.